Skip to main content
Top
Published in: BMC Nephrology 1/2014

Open Access 01-12-2014 | Research article

Comparative short-term safety of bolus versus maintenance iron dosing in hemodialysis patients: a replication study

Authors: Janet K Freburger, Alan R Ellis, Abhijit V Kshirsagar, Lily Wang, M Alan Brookhart

Published in: BMC Nephrology | Issue 1/2014

Login to get access

Abstract

Background

Recent research has reported that patients receiving bolus (frequent large doses to achieve iron repletion) versus maintenance dosing of iron have an increased short-term risk of infection, but a similar risk of cardiovascular events. We sought to determine whether these findings could be replicated using the same methods and a different data source.

Methods

Clinical data from 6,605 patients of a small U.S. dialysis provider merged with Medicare claims data were examined. Iron dosing patterns (bolus, maintenance, no iron) were identified during 1-month exposure periods and cardiovascular and infection-related outcomes were assessed during 3-month follow-up periods. The effects of bolus versus maintenance dosing were assessed using Cox proportional hazards regression analyses to estimate hazard ratios and semiparametric additive risk models to estimate hazard rate differences, controlling for demographic and clinical characteristics, laboratory values and medications, and comorbidities.

Results

48,050 exposure/follow-up periods were examined. 13.9 percent of the exposure periods were bolus dosing, 49.3 percent were maintenance dosing, and the remainder were no iron use. All of the adjusted hazard ratios were >1.00 for the infection-related outcomes, suggesting that bolus dosing increases the risk of these events. The effects were greatest for hospitalized for infection of any major organ system (hazard ratio 1.13 (1.03, 1.24)) and use of intravenous antibiotics (hazard ratio 1.08 (1.02, 1.15). When examining the subgroup of individuals with catheters, the hazard ratios for the infection-related outcomes were generally greater than in the overall sample. There was little association between type of dosing practice and cardiovascular outcomes.

Conclusions

Results of this study provide further evidence of the association between bolus dosing and increased infection risk, particularly in the subgroup of patients with a catheter, and of the lack of an association between dosing practices and cardiovascular outcomes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Besarab A, Kaiser JW, Frinak S: A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis. 1999, 34 (1): 21-28. 10.1016/S0272-6386(99)70103-4.CrossRefPubMed Besarab A, Kaiser JW, Frinak S: A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis. 1999, 34 (1): 21-28. 10.1016/S0272-6386(99)70103-4.CrossRefPubMed
2.
go back to reference Charytan C, Levin N, Al-Saloum M, Hafeez T, Gagnon S, Van Wyck DB: Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kidney Dis. 2001, 37 (2): 300-307. 10.1053/ajkd.2001.21293.CrossRefPubMed Charytan C, Levin N, Al-Saloum M, Hafeez T, Gagnon S, Van Wyck DB: Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kidney Dis. 2001, 37 (2): 300-307. 10.1053/ajkd.2001.21293.CrossRefPubMed
3.
go back to reference Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR: Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007, 18 (3): 975-984. 10.1681/ASN.2006091034.CrossRefPubMed Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR: Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007, 18 (3): 975-984. 10.1681/ASN.2006091034.CrossRefPubMed
4.
go back to reference Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Brookhart MA: The comparative short-term effectiveness of iron dosing and formulations in U.S. hemodialysis patients. Am J Med. 2013, 126 (6): 541-e541-541.e514CrossRefPubMed Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Brookhart MA: The comparative short-term effectiveness of iron dosing and formulations in U.S. hemodialysis patients. Am J Med. 2013, 126 (6): 541-e541-541.e514CrossRefPubMed
5.
go back to reference Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006, 355 (20): 2071-2084. 10.1056/NEJMoa062276.CrossRefPubMed Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006, 355 (20): 2071-2084. 10.1056/NEJMoa062276.CrossRefPubMed
6.
go back to reference Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, Mcgill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009, 361 (21): 2019-2032. 10.1056/NEJMoa0907845.CrossRefPubMed Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, Mcgill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009, 361 (21): 2019-2032. 10.1056/NEJMoa0907845.CrossRefPubMed
7.
go back to reference Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006, 355 (20): 2085-2098. 10.1056/NEJMoa065485.CrossRefPubMed Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006, 355 (20): 2085-2098. 10.1056/NEJMoa065485.CrossRefPubMed
8.
go back to reference Brewster UC: Intravenous iron therapy in end-stage renal disease. Semin Dial. 2006, 19 (4): 285-290. 10.1111/j.1525-139X.2006.00174.x.CrossRefPubMed Brewster UC: Intravenous iron therapy in end-stage renal disease. Semin Dial. 2006, 19 (4): 285-290. 10.1111/j.1525-139X.2006.00174.x.CrossRefPubMed
9.
go back to reference Parkkinen J, von Bonsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K: Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant. 2000, 15 (11): 1827-1834. 10.1093/ndt/15.11.1827.CrossRefPubMed Parkkinen J, von Bonsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K: Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant. 2000, 15 (11): 1827-1834. 10.1093/ndt/15.11.1827.CrossRefPubMed
10.
go back to reference Brewster UC, Perazella MA: Intravenous iron and the risk of infection in end-stage renal disease patients. Semin Dial. 2004, 17 (1): 57-60.PubMed Brewster UC, Perazella MA: Intravenous iron and the risk of infection in end-stage renal disease patients. Semin Dial. 2004, 17 (1): 57-60.PubMed
11.
go back to reference Bullen JJ, Rogers HJ, Spalding PB, Ward CG: Iron and infection: the heart of the matter. FEMS Immunol Med Microbiol. 2005, 43 (3): 325-330. 10.1016/j.femsim.2004.11.010.CrossRefPubMed Bullen JJ, Rogers HJ, Spalding PB, Ward CG: Iron and infection: the heart of the matter. FEMS Immunol Med Microbiol. 2005, 43 (3): 325-330. 10.1016/j.femsim.2004.11.010.CrossRefPubMed
12.
go back to reference Collins AJ, Ebben J, Ma JZ, Xia H: Iron dosing patterns and mortality [abstract]. J Am Soc Nephrol. 1998, 9: 250A- Collins AJ, Ebben J, Ma JZ, Xia H: Iron dosing patterns and mortality [abstract]. J Am Soc Nephrol. 1998, 9: 250A-
14.
go back to reference Martin-Malo A, Merino A, Carracedo J, Alvarez-Lara MA, Ojeda R, Soriano S, Crespo R, Ramirez R, Aljama P: Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol Dial Transplant. 2012, 27 (6): 2465-2471. 10.1093/ndt/gfr711.CrossRefPubMed Martin-Malo A, Merino A, Carracedo J, Alvarez-Lara MA, Ojeda R, Soriano S, Crespo R, Ramirez R, Aljama P: Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol Dial Transplant. 2012, 27 (6): 2465-2471. 10.1093/ndt/gfr711.CrossRefPubMed
15.
go back to reference Sevanian A, Hochstein P: Mechanisms and consequences of lipid peroxidation in biological systems. Annu Rev Nutr. 1985, 5: 365-390. 10.1146/annurev.nu.05.070185.002053.CrossRefPubMed Sevanian A, Hochstein P: Mechanisms and consequences of lipid peroxidation in biological systems. Annu Rev Nutr. 1985, 5: 365-390. 10.1146/annurev.nu.05.070185.002053.CrossRefPubMed
16.
go back to reference Berliner JA, Heinecke JW: The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med. 1996, 20 (5): 707-727. 10.1016/0891-5849(95)02173-6.CrossRefPubMed Berliner JA, Heinecke JW: The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med. 1996, 20 (5): 707-727. 10.1016/0891-5849(95)02173-6.CrossRefPubMed
17.
go back to reference Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002, 62 (5): 1524-1538. 10.1046/j.1523-1755.2002.00600.x.CrossRefPubMed Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002, 62 (5): 1524-1538. 10.1046/j.1523-1755.2002.00600.x.CrossRefPubMed
18.
go back to reference Brookhart MA, Freburger JK, Ellis K, Wang L, Winkelmayer WC, Kshirsagar AV: Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Nephrol Soc. 2013, 24 (7): 1151-1158. 10.1681/ASN.2012121164.CrossRef Brookhart MA, Freburger JK, Ellis K, Wang L, Winkelmayer WC, Kshirsagar AV: Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Nephrol Soc. 2013, 24 (7): 1151-1158. 10.1681/ASN.2012121164.CrossRef
19.
go back to reference Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Brookhart MA: The comparative short-term cardiovascular safety of intravenous iron dosing in hemodialysis patients. PLOS One. 2013, 8 (11): e78930-10.1371/journal.pone.0078930.CrossRefPubMedPubMedCentral Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Brookhart MA: The comparative short-term cardiovascular safety of intravenous iron dosing in hemodialysis patients. PLOS One. 2013, 8 (11): e78930-10.1371/journal.pone.0078930.CrossRefPubMedPubMedCentral
20.
go back to reference U.S. Renal Data System Coordinating Center: Researcher's Guide to the USRDS Database,2011. 2012, Bethesda, MD: National Institutes of Health, NIDDK U.S. Renal Data System Coordinating Center: Researcher's Guide to the USRDS Database,2011. 2012, Bethesda, MD: National Institutes of Health, NIDDK
21.
go back to reference Elixhauser A, Steiner C, Harris DR, Coffey RM: Comorbidity measures for use with administrative data. Med Care. 1998, 36 (1): 8-27. 10.1097/00005650-199801000-00004.CrossRefPubMed Elixhauser A, Steiner C, Harris DR, Coffey RM: Comorbidity measures for use with administrative data. Med Care. 1998, 36 (1): 8-27. 10.1097/00005650-199801000-00004.CrossRefPubMed
22.
go back to reference Xie X, Strickler HD, Xue X: Additive hazard regression models: an application to the natural history of human papillomavirus. Comput Math Methods Med. 2013, 2013: 796270-CrossRefPubMedPubMedCentral Xie X, Strickler HD, Xue X: Additive hazard regression models: an application to the natural history of human papillomavirus. Comput Math Methods Med. 2013, 2013: 796270-CrossRefPubMedPubMedCentral
23.
go back to reference Lin DY, Wei LJ: The robust inference for the proportional hazards model. J Am Stat Assoc. 1989, 84: 1074-1078. 10.1080/01621459.1989.10478874.CrossRef Lin DY, Wei LJ: The robust inference for the proportional hazards model. J Am Stat Assoc. 1989, 84: 1074-1078. 10.1080/01621459.1989.10478874.CrossRef
24.
go back to reference Robins JM, Hernan MA, Brumback B: Marginal structural models and causal inference in epidemiology. Epidemiology. 2000, 11 (5): 550-560. 10.1097/00001648-200009000-00011.CrossRefPubMed Robins JM, Hernan MA, Brumback B: Marginal structural models and causal inference in epidemiology. Epidemiology. 2000, 11 (5): 550-560. 10.1097/00001648-200009000-00011.CrossRefPubMed
25.
go back to reference Hernan MA, Brumback B, Robins JM: Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000, 11 (5): 561-570. 10.1097/00001648-200009000-00012.CrossRefPubMed Hernan MA, Brumback B, Robins JM: Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000, 11 (5): 561-570. 10.1097/00001648-200009000-00012.CrossRefPubMed
Metadata
Title
Comparative short-term safety of bolus versus maintenance iron dosing in hemodialysis patients: a replication study
Authors
Janet K Freburger
Alan R Ellis
Abhijit V Kshirsagar
Lily Wang
M Alan Brookhart
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2014
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-15-154

Other articles of this Issue 1/2014

BMC Nephrology 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.